1018678-39-1

Basic information

• Product Name: 4-Chloro-2-(trifluoroMethyl)nicotinic acid
• Synonyms: 4-Chloro-2-(trifluoroMethyl)nicotinic acid
• CAS NO: 1018678-39-1
• Molecular Formula: C7H3ClF3NO2
• Molecular Weight: 225.5524296
• Mol File: 1018678-39-1.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-Chloro-2-(trifluoroMethyl)nicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-2-(trifluoroMethyl)nicotinic acid(1018678-39-1)
• EPA Substance Registry System: 4-Chloro-2-(trifluoroMethyl)nicotinic acid(1018678-39-1)

Safety Data

• Hazardous Substances Data: 1018678-39-1(Hazardous Substances Data)

Usage

Uses

4-Chloro-2-(trifluoromethyl)nicotinic Acid is used in preparation of cyanotriazole compounds for the treatment of leishmaniasis, African trypanosomiasis and Chagas disease.

InChI:InChI=1S/C7H3ClF3NO2/c8-3-1-2-12-5(7(9,10)11)4(3)6(13)14/h1-2H,(H,13,14)

Upstream product

• 131747-43-8 2-(trifluoromethyl)nicotinic acid 

Downstream Products

• 870101-37-4 ethyl 4-amino-2-(trifluoromethyl)nicotinate 

Relevant articles and documents

CYANOTRIAZOLE COMPOUNDS AND USES THEREOF

The present invention provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof: (I) wherein R1, R2, R3, and R4 are as defined herein. The present invention further provides therapeutic uses of these compounds, for example against human African typanosomiasis; pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

HETEROCYCLIC COMPOUND

Provided is a compound having a superior FLAP inhibitory action and useful as a prophylactic or therapeutic agent for arteriosclerosis and the like, and a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present DESCRIPTION, or a salt thereof.

PYRIDO [4,3-d] PYRIMIDIN-4 (3H) -ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS

The present invention is directed to novel pyrido[4,3-d]pyrimidin-4(3H)-one derivatives and pharmaceutically acceptable salts thereof of structural formula I wherein the variables R1, R2, R3, R4 and R5 are as described herein. Also provided are pharmaceutical compositions comprising the compounds of formula I as well as methods of treatment employing compounds of formula I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget's disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy.